TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Transcranial DC Stimulation Coupled With Constraint Induced Movement Therapy on Motor Function in Stroke Patients
Brief Summary: The purpose of this study is to determine whether noninvasive brain stimulation associated with motor learning offers an additional benefit than motor learning alone in patients with stroke.

The investigators hypothesis is that active transcranial direct current stimulation (tDCS) combined with constraint induced movement therapy (CIMT) will induce a greater motor function improvement as compared with sham tDCS combined with CIMT.


Options:
A: Arm Label: Real stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) | Arm Label: Sham stimulation; Type: SHAM_COMPARATOR; Interventions: Device: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) | Intervention Type: DEVICE; Name: tdcs (ELDITH, Neuroconn, Ilmenau, Germany); Assigned to Arm(s): Real stimulation, Sham stimulation
B: Arm Label: active tDCS + CIMT - stroke patients; Type: EXPERIMENTAL; Interventions: Device: transcranial direct current stimulation (tDCS), Procedure: constraint induced movement therapy (CIMT) | Arm Label: active tDCS + CIMT - Healthy; Type: EXPERIMENTAL; Interventions: Device: transcranial direct current stimulation (tDCS), Procedure: constraint induced movement therapy (CIMT) | Arm Label: tACS - Healthy Subjects; Type: EXPERIMENTAL; Interventions: Device: transcranial alternating current stimulation (tACS) | Arm Label: sham tDCS + CIMT - stroke patients; Type: SHAM_COMPARATOR; Interventions: Device: transcranial direct current stimulation (tDCS), Procedure: constraint induced movement therapy (CIMT) | Arm Label: sham tDCS + CIMT - Healthy; Type: SHAM_COMPARATOR; Interventions: Device: transcranial direct current stimulation (tDCS), Procedure: constraint induced movement therapy (CIMT) | Arm Label: sham tACS - Healthy Subjects; Type: SHAM_COMPARATOR; Interventions: Device: transcranial alternating current stimulation (tACS) | Intervention Type: DEVICE; Name: transcranial direct current stimulation (tDCS); Assigned to Arm(s): active tDCS + CIMT - Healthy, active tDCS + CIMT - stroke patients, sham tDCS + CIMT - Healthy, sham tDCS + CIMT - stroke patients | Intervention Type: PROCEDURE; Name: constraint induced movement therapy (CIMT); Assigned to Arm(s): active tDCS + CIMT - Healthy, active tDCS + CIMT - stroke patients, sham tDCS + CIMT - Healthy, sham tDCS + CIMT - stroke patients | Intervention Type: DEVICE; Name: transcranial alternating current stimulation (tACS); Assigned to Arm(s): sham tACS - Healthy Subjects, tACS - Healthy Subjects
C: Arm Label: subcortical; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: cortical; Type: EXPERIMENTAL; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): cortical, subcortical
D: Arm Label: Sham; Type: PLACEBO_COMPARATOR; Interventions: Device: tDCS | Arm Label: tDCS; Type: EXPERIMENTAL; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Sham, tDCS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hepatitis C Translating Initiatives for Depression Into Solutions
Brief Summary: Chronic infection with hepatitis C (CHC) is a common and expensive condition, and it disproportionately affects Veterans. Treatment with antiviral therapy reduces liver disease progression and improves health related quality of life. However, \~70% of Veterans with CHC are considered ineligible for antiviral treatment. Most of these patients are excluded due to the presence of co-existing depression and substance use. The proposed project will adapt and adopt an evidence-based collaborative depression care model in CHC clinics. By removing the leading contraindication for antiviral treatment, this project will potentially yield benefits that go far beyond the obvious quality of life benefit from antidepressant therapy itself.


Options:
A: Arm Label: Arm 1: Depression Collaborative Care; Type: EXPERIMENTAL; Interventions: Other: Depression collaborative care model | Arm Label: Arm 2: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Depression collaborative care model; Assigned to Arm(s): Arm 1: Depression Collaborative Care
B: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Telemedicine intervention | Intervention Type: BEHAVIORAL; Name: Telemedicine intervention; Assigned to Arm(s): Arm 1
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmaceutical care program for antidepressant treatment | Intervention Type: BEHAVIORAL; Name: Pharmaceutical care program for antidepressant treatment; Assigned to Arm(s): Intervention Group
D: Arm Label: Arm 1: Collaborative Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Interventions | Arm Label: Arm 2: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Collaborative Care Interventions; Assigned to Arm(s): Arm 1: Collaborative Care Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion of Fresh Frozen Plasma in Non-bleeding ICU Patients
Brief Summary: With the aim to restrict inappropriate fresh frozen plasma (FFP) transfusions to critically ill patients, a randomized clinical trial will be conducted in a subgroup of intensive care (ICU) patients undergoing an invasive procedure. The objective is to assess the effectiveness and costs of omitting prophylactic FFP transfusion compared to current practice of prophylactic transfusion, in non-bleeding ICU patients with a coagulopathy.


Options:
A: Intervention Type: PROCEDURE; Name: central venous catheter application; Assigned to Arm(s): N/A
B: Arm Label: 1:1:1 Blood Transfusion Ratio; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1:1:1 Blood Transfusion Ratio | Arm Label: 1:1:2 Blood Transfusion Ratio; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1:1:2 Blood Transfusion Ratio | Intervention Type: BIOLOGICAL; Name: 1:1:1 Blood Transfusion Ratio; Assigned to Arm(s): 1:1:1 Blood Transfusion Ratio | Intervention Type: BIOLOGICAL; Name: 1:1:2 Blood Transfusion Ratio; Assigned to Arm(s): 1:1:2 Blood Transfusion Ratio
C: Arm Label: Quarantined FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Arm Label: Methylene blue FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Arm Label: Solvent detergent FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Intervention Type: OTHER; Name: plasma; Assigned to Arm(s): Methylene blue FFP, Quarantined FFP, Solvent detergent FFP
D: Arm Label: No FFP transfusion prior to intervention; Type: EXPERIMENTAL; Interventions: Other: omitting FFP transfusion before an intervention | Arm Label: FFP transfusion prior to intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: omitting FFP transfusion before an intervention; Assigned to Arm(s): No FFP transfusion prior to intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
Brief Summary: Multiple Sclerosis (MS) is the most common neurological disorder causing disability in young adults. The management of MS-patients requires treatment with disease-modifying agents, monoclonal antibodies such as natalizumab or immunosuppressants. Natalizumab showed good efficacy and is approved for treatment of relapsing MS with a number of restrictions due to safety issues. Cognitive data related to natalizumab treatment are still scarce. Interferon-beta-1b is approved for high-frequency, subcutaneous (sc) administration in the treatment of multiple sclerosis. It reduces the relapse rate, severity, hospitalisation and the disease activity as seen on MRI.

This is a pilot study to explore the concept of de-escalating natalizumab treatment to interferon-beta-1b e.o.d compared to continuous treatment with natalizumab in patients with relapsing-remitting multiple sclerosis previously treated with natalizumab for 12 months. The study is designed as prospective, controlled, randomized, rater-blinded, parallel-group, two arm, mono-centric including patients of the Ticino Cohort. One arm will be treated with Interferon-beta 1b 250mcg given subcutaneously every other day, the other with Natalizumab 300 mg given intravenously (i.v.), every four weeks. The treatment duration is 12 months, the follow-up period 12 months. The time to first on-study relapse will be compared between the to treatment arms (primary outcome). Other efficacy parameter include clinical and radiological parameters, patient reported outcome on quality of life and fatigue. Safety is assessed by reports of adverse events.


Options:
A: Arm Label: Threshold estimates; Type: EXPERIMENTAL; Interventions: Other: descriptive case-scenarios | Arm Label: Alternative threshold estimates; Type: ACTIVE_COMPARATOR; Interventions: Other: descriptive case-scenarios | Intervention Type: OTHER; Name: descriptive case-scenarios; Assigned to Arm(s): Alternative threshold estimates, Threshold estimates
B: Arm Label: Ponesimod; Type: EXPERIMENTAL; Interventions: Drug: ponesimod | Arm Label: Teriflunomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: teriflunomide | Intervention Type: DRUG; Name: ponesimod; Assigned to Arm(s): Ponesimod | Intervention Type: DRUG; Name: teriflunomide; Assigned to Arm(s): Teriflunomide
C: Arm Label: Natalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Natalizumab | Arm Label: Interferon-beta-1b; Type: EXPERIMENTAL; Interventions: Drug: interferon beta-1b | Intervention Type: DRUG; Name: interferon beta-1b; Assigned to Arm(s): Interferon-beta-1b | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Natalizumab
D: Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.
Brief Summary: This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.


Options:
A: Arm Label: Anagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anagliptin | Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin | Intervention Type: DRUG; Name: Anagliptin; Assigned to Arm(s): Anagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin
B: Arm Label: Exenatide Once Weekly; Type: EXPERIMENTAL; Interventions: Drug: Exenatide Once Weekly | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Exenatide Once Weekly; Assigned to Arm(s): Exenatide Once Weekly | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Empagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Lira 1.8 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Innovative Home Stroke Rehabilitation and Monitoring System
Brief Summary: The purpose of this research is to evaluate a therapy delivery system for stroke patients that provide accessible, affordable stroke care. User-friendly home therapy robots and a telerehabilitation system are combined to monitor and provide therapy that is accessible for patients in rural and underserved locations. The robotic-based home therapy intervention will produce significantly greater improvement in upper extremity motor function than Usual and Customary Care enhanced with a (non-robotic) home therapy upper extremity rehabilitation program at the end of 8 weeks of home therapy.


Options:
A: Arm Label: Tele-visit Group; Type: EXPERIMENTAL; Interventions: Behavioral: TR intervention, Behavioral: In-home messaging device. | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: TR intervention; Assigned to Arm(s): Tele-visit Group | Intervention Type: BEHAVIORAL; Name: In-home messaging device.; Assigned to Arm(s): Tele-visit Group | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care Group
B: Arm Label: Monitoring and Feedback; Type: EXPERIMENTAL; Interventions: Device: Wrist-worn wearables | Arm Label: Monitoring; Type: PLACEBO_COMPARATOR; Interventions: Device: Wrist-worn wearables | Intervention Type: DEVICE; Name: Wrist-worn wearables; Assigned to Arm(s): Monitoring, Monitoring and Feedback
C: Arm Label: effects of a incentive program for physical activity; Type: EXPERIMENTAL; Interventions: Other: incentive program for physical activity | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: incentive program for physical activity; Assigned to Arm(s): effects of a incentive program for physical activity
D: Arm Label: Hand Mentor Therapy; Type: EXPERIMENTAL; Interventions: Device: Hand Mentor (TM) robotic stroke therapy device | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Home Therapy Program | Intervention Type: DEVICE; Name: Hand Mentor (TM) robotic stroke therapy device; Assigned to Arm(s): Hand Mentor Therapy | Intervention Type: DEVICE; Name: Home Therapy Program; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Innovative Home Stroke Rehabilitation and Monitoring System
Brief Summary: The purpose of this research is to evaluate a therapy delivery system for stroke patients that provide accessible, affordable stroke care. User-friendly home therapy robots and a telerehabilitation system are combined to monitor and provide therapy that is accessible for patients in rural and underserved locations. The robotic-based home therapy intervention will produce significantly greater improvement in upper extremity motor function than Usual and Customary Care enhanced with a (non-robotic) home therapy upper extremity rehabilitation program at the end of 8 weeks of home therapy.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Device: Robotic Upper Extremity Neurorehabilitation | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional Upper Extremity Exercise Group | Intervention Type: DEVICE; Name: Robotic Upper Extremity Neurorehabilitation; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Traditional Upper Extremity Exercise Group; Assigned to Arm(s): Arm 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: robot therapy (ARMin) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional therapy | Intervention Type: DEVICE; Name: robot therapy (ARMin); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: conventional therapy; Assigned to Arm(s): 2
C: Arm Label: Hand Mentor Therapy; Type: EXPERIMENTAL; Interventions: Device: Hand Mentor (TM) robotic stroke therapy device | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Home Therapy Program | Intervention Type: DEVICE; Name: Hand Mentor (TM) robotic stroke therapy device; Assigned to Arm(s): Hand Mentor Therapy | Intervention Type: DEVICE; Name: Home Therapy Program; Assigned to Arm(s): Control
D: Arm Label: Experimental Group (EG); Type: EXPERIMENTAL; Interventions: Device: Robot therapy (NeReBot), Other: Conventional therapy | Arm Label: Control Group (CG); Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional therapy | Intervention Type: DEVICE; Name: Robot therapy (NeReBot); Assigned to Arm(s): Experimental Group (EG) | Intervention Type: OTHER; Name: Conventional therapy; Assigned to Arm(s): Control Group (CG), Experimental Group (EG)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Innovative Home Stroke Rehabilitation and Monitoring System
Brief Summary: The purpose of this research is to evaluate a therapy delivery system for stroke patients that provide accessible, affordable stroke care. User-friendly home therapy robots and a telerehabilitation system are combined to monitor and provide therapy that is accessible for patients in rural and underserved locations. The robotic-based home therapy intervention will produce significantly greater improvement in upper extremity motor function than Usual and Customary Care enhanced with a (non-robotic) home therapy upper extremity rehabilitation program at the end of 8 weeks of home therapy.


Options:
A: Arm Label: Virtual reality; Type: EXPERIMENTAL; Interventions: Device: Virtual Reality | Arm Label: Conventional arm training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional arm training | Intervention Type: DEVICE; Name: Virtual Reality; Assigned to Arm(s): Virtual reality | Intervention Type: BEHAVIORAL; Name: Conventional arm training; Assigned to Arm(s): Conventional arm training
B: Arm Label: Virtual Reality Therapy; Type: EXPERIMENTAL; Interventions: Other: Virtual Reality | Arm Label: Traditional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional Therapy | Intervention Type: OTHER; Name: Virtual Reality; Assigned to Arm(s): Virtual Reality Therapy | Intervention Type: OTHER; Name: Traditional Therapy; Assigned to Arm(s): Traditional Therapy
C: Arm Label: Hand Mentor Therapy; Type: EXPERIMENTAL; Interventions: Device: Hand Mentor (TM) robotic stroke therapy device | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Home Therapy Program | Intervention Type: DEVICE; Name: Hand Mentor (TM) robotic stroke therapy device; Assigned to Arm(s): Hand Mentor Therapy | Intervention Type: DEVICE; Name: Home Therapy Program; Assigned to Arm(s): Control
D: Arm Label: Nintendo Wii FitTM; Type: EXPERIMENTAL; Interventions: Other: Wii Fit | Arm Label: Lower extremity exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Lower Extremity Exercise | Intervention Type: OTHER; Name: Wii Fit; Assigned to Arm(s): Nintendo Wii FitTM | Intervention Type: OTHER; Name: Lower Extremity Exercise; Assigned to Arm(s): Lower extremity exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease
Brief Summary: In a dose escalation study we will determine the safety and preliminary efficacy of allogeneic bone marrow mesenchymal stem cells (bmMSCs) in the induction of response for active fistulizing Crohn's Disease (CD).


Options:
A: Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Procedure: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection. | Arm Label: Cohort 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection. | Arm Label: Cohort 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection. | Arm Label: Cohort 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection. | Intervention Type: PROCEDURE; Name: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.; Assigned to Arm(s): Control group | Intervention Type: PROCEDURE; Name: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3
B: Arm Label: Mesenchymal stromal cells; Type: EXPERIMENTAL; Interventions: Drug: Mesenchymal stromal cells (MSC) for infusion | Intervention Type: DRUG; Name: Mesenchymal stromal cells (MSC) for infusion; Assigned to Arm(s): Mesenchymal stromal cells
C: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Mesenchymal Stem Cells; Type: EXPERIMENTAL; Interventions: Drug: Mesenchymal Stem Cells | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Mesenchymal Stem Cells; Assigned to Arm(s): Mesenchymal Stem Cells | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Five Year Follow-up of Internet-based Cognitive Behaviour Therapy for Social Anxiety Disorder
Brief Summary: Social anxiety disorder (SAD) is one of the most prevalent anxiety disorders in the western world. Cognitive behavioural therapy (CBT) is the psychological treatment that has the largest empirical support. However, the availability to CBT is very limited in Sweden due to lack of therapists with proper training. Therefore it is important to evaluate alternative forms of treatment that are more time efficient. One of these methods is Internet based self-help therapy, which has proven to be an effective treatment for social anxiety disorder.

In this study, the investigators aim to conduct a follow-up assessment five years after completed Internet-based CBT. Participants received treatment within the context of a randomised controlled trial conducted in 2005. Thus, in the present study there will be no treatment interventions, only assessment.


Options:
A: Arm Label: Internet-based CBT; Type: N/A; Interventions: N/A
B: Arm Label: Internet CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based cognitive behavior therapy (CBT). | Arm Label: Group CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Group CBT | Intervention Type: BEHAVIORAL; Name: Internet-based cognitive behavior therapy (CBT).; Assigned to Arm(s): Internet CBT | Intervention Type: BEHAVIORAL; Name: Group CBT; Assigned to Arm(s): Group CBT
C: Arm Label: Tailored Internet-delivered CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Internet-administrated CBT-Treatment | Arm Label: Waitlist; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Waitlist | Intervention Type: BEHAVIORAL; Name: Tailored Internet-administrated CBT-Treatment; Assigned to Arm(s): Tailored Internet-delivered CBT | Intervention Type: BEHAVIORAL; Name: Waitlist; Assigned to Arm(s): Waitlist
D: Arm Label: iSOFIE; Type: EXPERIMENTAL; Interventions: Other: iSOFIE | Arm Label: Waitlist control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: iSOFIE; Assigned to Arm(s): iSOFIE

Answer: A